Literature DB >> 10912918

Apolipoprotein E4 promotes the early deposition of Abeta42 and then Abeta40 in the elderly.

L C Walker1, J Pahnke, M Madauss, S Vogelgesang, A Pahnke, E W Herbst, D Stausske, R Walther, C Kessler, R W Warzok.   

Abstract

The apolipoprotein Eepsilon4 allele (ApoEepsilon4) is associated with a selective increase in deposition of the 40-amino acid form of the beta-amyloid peptide (Abeta40) in endstage Alzheimer's disease. To determine how apoE genotype affects the early events in beta-amyloid pathogenesis, we analyzed the medial temporal lobes of 244 elderly persons who were not clinically demented using antibodies selective for the C termini of Abeta40 and Abeta42. We found that: (1) the number of both Abeta42- and Abeta40-positive senile plaques increase with age; (2) Abeta42 appears at younger ages, and in more amyloid deposits, than does Abeta40 in all ApoE groups; (3) when compared at similar ages, older persons with ApoEepsilon4 are more likely to have Abeta42- and Abeta40-immunoreactive deposits than are persons without ApoEepsilon4; (4) Abeta40-containing plaques arise at least a decade later than do Abeta42 plaques, and are seldom found in the medial temporal lobe of older persons lacking ApoEepsilon4; and (5) in the absence of overt Alzheimer's disease, cerebral amyloid angiopathy is rare in the elderly, but in our sample was significantly augmented in ApoEepsilon4 homozygotes. We conclude that ApoEepsilon4 hastens the onset of Abeta42 deposition in the senescent brain, which in turn fosters the earlier evolution of fibrillar, Abeta40-positive plaques, thereby increasing the risk of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10912918     DOI: 10.1007/s004010051190

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  25 in total

Review 1.  Nonhuman primate models of Alzheimer-like cerebral proteopathy.

Authors:  Eric Heuer; Rebecca F Rosen; Amarallys Cintron; Lary C Walker
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 2.  Clinico-pathologic function of cerebral ABC transporters - implications for the pathogenesis of Alzheimer's disease.

Authors:  Jens Pahnke; Olaf Wolkenhauer; Markus Krohn; Lary C Walker
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

3.  Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain.

Authors:  M Morishima-Kawashima; N Oshima; H Ogata; H Yamaguchi; M Yoshimura; S Sugihara; Y Ihara
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

4.  Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice.

Authors:  M D Kane; W J Lipinski; M J Callahan; F Bian; R A Durham; R D Schwarz; A E Roher; L C Walker
Journal:  J Neurosci       Date:  2000-05-15       Impact factor: 6.167

5.  Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease.

Authors:  Jean-Cosme Dodart; Robert A Marr; Milla Koistinaho; Beth M Gregersen; Seema Malkani; Inder M Verma; Steven M Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-18       Impact factor: 11.205

Review 6.  The Exceptional Vulnerability of Humans to Alzheimer's Disease.

Authors:  Lary C Walker; Mathias Jucker
Journal:  Trends Mol Med       Date:  2017-05-05       Impact factor: 11.951

7.  Effects of human apolipoprotein E isoforms on the amyloid beta-protein concentration and lipid composition in brain low-density membrane domains.

Authors:  Maho Morishima-Kawashima; Xianlin Han; Yu Tanimura; Hiroki Hamanaka; Mariko Kobayashi; Takashi Sakurai; Minesuke Yokoyama; Koji Wada; Nobuyuki Nukina; Shinobu C Fujita; Yasuo Ihara
Journal:  J Neurochem       Date:  2007-05       Impact factor: 5.372

8.  Systemic treatment with liver X receptor agonists raises apolipoprotein E, cholesterol, and amyloid-β peptides in the cerebral spinal fluid of rats.

Authors:  Sokreine Suon; Jie Zhao; Stephanie A Villarreal; Nikesh Anumula; Mali Liu; Linda M Carangia; John J Renger; Celina V Zerbinatti
Journal:  Mol Neurodegener       Date:  2010-10-29       Impact factor: 14.195

9.  Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease.

Authors:  Rebecca F Rosen; Brian J Ciliax; Thomas S Wingo; Marla Gearing; Jeromy Dooyema; James J Lah; Jorge A Ghiso; Harry LeVine; Lary C Walker
Journal:  Acta Neuropathol       Date:  2009-08-19       Impact factor: 17.088

10.  Use of copper and insulin-resistance to accelerate cognitive deficits and synaptic protein loss in a rat Abeta-infusion Alzheimer's disease model.

Authors:  Aynun N Begum; Fusheng Yang; Edmond Teng; Shuxin Hu; Mychica R Jones; Emily R Rosario; Walter Beech; Beverly Hudspeth; Oliver J Ubeda; Greg M Cole; Sally A Frautschy
Journal:  J Alzheimers Dis       Date:  2008-12       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.